Meal Monotony for Weight Loss; Genes Explain GLP-1 Response; Menopause Drug Boom

Eating the same meals every day may aid in weight loss, according to a study of real-time food tracking data. (Health Psychology)

The prevalence of youth-onset type 2 diabetes increased substantially from 2013 to 2024, rising from 0.73 to 1.24 cases per 1,000 youths, a U.S. study showed. (New England Journal of Medicine)

Mutations in the GLP1R and GIPR genes — which encode targets for GLP-1 drugs — could help explain why some patients respond differently to treatment class and who is more prone to side effects. (Nature)

A group of New York nuns operating a nursing facility sued the state over a mandate requiring them to provide specific care for transgender patients. (USA Today)

The achondroplasia treatment navepegritide (Yuviwel) is now available following its FDA approval in February, said maker Ascendis Pharma.

The FDA will require postmarketing studies on orforglipron (Foundayo) to assess the risks of delayed gastric emptying, liver injury, cardiovascular events, and exposure to the drug during lactation. (Reuters via CNBC)

Menopausal hormone drugs have made a multibillion dollar comeback after the FDA dropped boxed safety warnings from several products. (Bloomberg via MSN)

Guideline-directed treatments — including SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and GLP-1 drugs — can be combined for chronic kidney disease with type 2 diabetes, researchers said, though questions on optimal initiation sequence still linger. (Journal of Clinical Endocrinology & Metabolism)

Use of semaglutide (Ozempic, Wegovy) was tied to improvements in liver health independent of weight loss, findings from a mouse study suggested. (Cell Metabolism)

Texas Attorney Gen­er­al Ken Paxton launched an investigation into clothing brand Lululemon over the potential presence of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” in activewear.

GLP-1 medication trailblazer Lotte Bjerre Knudsen, DMSc, who led the team that first discovered the peptide’s therapeutic potential, is leaving Novo Nordisk after 36 years, she announced on LinkedIn.